Guardant Health and Zephyr AI Announce Strategic Partnership to Advance Precision Oncology

A groundbreaking collaboration between precision oncology company Guardant Health and AI leader Zephyr AI aims to unlock new insights for personalized oncology treatments. By combining Guardant's industry-leading molecular data with Zephyr's advanced analytics platform, the partnership will accelerate research and development for biopharma partners, generating predictions of targeted cancer therapy response validated by real-world data.

Key Takeaways:

• The partnership will integrate Guardant Health's multimodal real-world data and precision oncology insights with Zephyr AI's proprietary AI technologies to accelerate research and development for biopharma partners.
• The collaboration will generate predictions of targeted cancer therapy response validated by real-world data, integrating biologic interpretability features to provide actionable scientific intelligence.
• The partnership will enable more precise, scalable, and impactful oncology solutions by converging unmatched real-world data, leading-edge diagnostics, and cutting-edge machine learning.
• Guardant Health and Zephyr AI will supercharge discovery and development needed to transform cancer treatment and deliver on the promise of personalized medicines for cancer patients.
• The partnership will be integrated with Guardant's broader suite of Infinity AI capabilities, exemplifying both companies' commitment to harnessing AI and multimodal data to empower oncologists, researchers, and biopharma developers.

Statistics:

• Guardant Health has been transforming patient care and accelerating new cancer therapies since its founding in 2012, providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and AI analytics.
• The partnership will unlock new insights for personalized oncology treatments, enabling more precise, scalable, and impactful oncology solutions.
• Guardant Health's tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.
• The recommended forward-looking statements include an obligation to update any statement in light of such future events or developments.

Sources:

• "Guardant Health (Nasdaq: GH), a leading precision oncology company," businesswire.com
• "About Guardant Health", guardanthealth.com
• "About Zephyr AI", zephyrai.bio